Videos

Optimizing the Management of HER2+ Inflammatory Breast Cancer

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the significance of his findings when combining an anti-CTLA-4 and anti-PD-1 in patients with multiple myeloma. He sought out to find whether these 2 drugs could be combined safely after an autologous stem cell transplant. 

Improving the Treatment of Locally Advanced Pancreatic Cancer

Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.

Brian T. Hill, MD, PhD, director of Lymphoid Malignancies at the Cleveland Clinic, discusses current combinations being investigated for the treatment of patients with mantle cell lymphoma.

Treatment Considerations for Unresectable Locally Advanced NSCLC

Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm. 

Daniel J. DeAngelo, MD, PhD, associate professor at the Harvard School of Medicine and a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, highlighted the 4 FDA approvals in the last year for the treatment of patients with acute myeloid leukemia.

Casey Cosgrove, MD, a fellow at the Ohio State Comprehensive Cancer Center, discussed a pilot trial that screened patients with endometrial cancers for Lynch syndrome.The potential impact of this study could lead to the prevention of endometrial, ovarian, and colorectal cancers in the future, Cosgrove said. 

Mario M. Leitao, Jr, MD, FACOG, FACS, program director of Gynecologic Oncology at Memorial Sloan Kettering Cancer Center, discusses what is currently being investigated in the treatment landscape of ovarian cancers.

Amanda Ramos, MD, a first-year fellow at the Massachusetts General Hospital in Boston, discusses the future potential of checkpoint inhibition therapy in the treatment of patients with recurrent endometrial cancers.